MedTrace Logo

Osilodrostat for the Treatment of Non-Cushing's Disease Cushing's Syndrome

NCT05633953 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 103

Last updated 2025-02-10

Study results available
· View outcomes & findings →

Summary

This is a multi-centre, observational, non-comparative, retrospective cohort study designed to evaluate the long-term safety and effectiveness of osilodrostat in non-CD CS patients. Patients treated with oral osilodrostat regardless of the duration of their treatment will be followed retrospectively for up to 36 months after initiating osilodrostat.

Conditions

Interventions

DRUG

Osilodrostat

oral administration

Sponsors & Collaborators

  • RECORDATI GROUP

    lead INDUSTRY

Principal Investigators

  • Mario M MALDONADO, MD · RECORDATI GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-01-16
Primary Completion
2023-09-30
Completion
2023-10-30
FDA Drug
Yes

Countries

  • France

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05633953 on ClinicalTrials.gov